Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
← catalyst calendarNCT06701331 · readout ≤ 165 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
99actual
Sites
25
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-22 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: Placebo — also filed as ABT-494, RINVOQ®
- Drug: Upadacitinib — also filed as ABT-494, RINVOQ®
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving Eczema Area and Severity Index (EASI) 75
measured At Week 12
Number of Participants With Adverse Events
measured From first dose of study drug until 30 days following last dose of study drug (up to approximately 56 weeks)
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed